Frazier Healthcare Partners launches Recida Therapeutics to develop novel therapeutics for serious antibiotic-resistant infections

This article was originally published here

Recida’s lead program, RC-01, is a novel, IND-stage LpxC inhibitor for the treatment of multidrug-resistant gram-negative infections. Recida has licensed development and commercialization rights to RC-01 from FUJIFILM

The post Frazier Healthcare Partners launches Recida Therapeutics to develop novel therapeutics for serious antibiotic-resistant infections appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply